Bavarian Nordic vaccine helps prolong life in prostate cancer trial

February 24, 2015 7:42 PM

3 0

(Reuters) - An experimental therapeutic vaccine from Danish drugmaker Bavarian Nordic helped significantly extend survival in patients with advanced prostate cancer, according to results of a small early-stage trial conducted by the U.S. National Cancer Institute.

Shares of Bavarian Nordic closed up almost 12 percent in Copenhagen after the company released the data on Tuesday.

Also read: Intel reports better-than-expected earnings as data center chips grow 13% to $4.5 billion

Read more

To category page